

bjclub

breastJournalClub

20-21 NOVEMBRE 2015
TRIESTE

PREMIO MIGLIORE STUDIO ITALIANO
VALENTINA GUARNERI

PREMIO SPECIALIZZANDO PER MIGLIORE STUDIO
MARTA BONOTTO

PRESENTAZIONE GERMAN BREAST GROUP
MICHAEL UNTCH

BOARD

Alberto Bottini
Francesco Cognetti
Pierfranco Conte
Michelino De Laurentiis
Sabino De Placido
Luigi Dogliotti
Luca Gianni
Giorgio Mustacchi
Paolo Pronzato
Fabio Puglisi

ECM

Il corso ha ottenuto nr. 7 CREDITI
ECM per le seguenti discipline:
Biologia, Oncologia, Radioterapia,
Chirurgia Generale,
Anatomia Patologica,
Patologia Clinica

CON IL PATROCINIO
DELL'ASSOCIAZIONE ITALIANA
DI ONCOLOGIA MEDICA

Aiom
Associazione Italiana di Oncologia Medica

PROGETTO ECM E SEGRETARIA ORGANIZZATIVA

over
group

Via Pagliari, 4 26100 Cremona
tel 0372 23310 fax 0372 569605
info@overgroup.eu
infowww.overgroup.eu

CON IL CONTRIBUTO INCONDIZIONATO DI

Celgene

bjclub

breastJournalClub

20-21 NOVEMBRE 2015
TRIESTE

STARHOTELS SAVOIA EXCELSIOR PALACE
Riva del Mandracchio, 4

PRESIDENTI DEL CONGRESSO
GIORGIO MUSTACCHI
FABIO PUGLISI

OSPITE INTERNAZIONALE
OLIVIA PAGANI

20 NOVEMBER 2015

16:00

Welcome and introduction

16:15

BEST INTERNATIONAL STUDY

G. Mustacchi, F. Puglisi,

16:20

Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer

O. Pagani

16:50

Discussion
P.F. Conte

17:00

BEST "MADE IN ITALY" STUDY

F. Cognetti

17:05

Double-blind, placebo-controlled, multi-center, randomized, phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative, operable breast cancer

V. Guarneri

17:30

Discussion
P. Pronzato

17:45

BEST STUDY BY ITALIAN POSTGRADUATE STUDENTS

S. De Placido, A. Sapino

17:50

Measures of outcome in metastatic breast cancer:

insights from a real-world scenario

M. Bonotto

18:20

Discussion

M. De Laurentiis

18:35

Fine lavori

21 NOVEMBER 2015

09:00

BEST RESEARCH BY YOUNG INVESTIGATORS

V. Adamo, S. Gori

Circulating and disseminated tumor cells from breast cancer patient-derived xenograft-bearing mice as a novel model to study metastasis

M. Giuliano

DISCUSSANT: C. Tondini

Long-term outcome results of the phase III PROMISE-GIM6 study evaluating the

role of LHRH analog (LHRHa) during chemotherapy (CT) as a strategy to reduce ovarian failure in early breast cancer (BC) patients

M. Lambertini

DISCUSSANT: L. Del Mastro

09:45

NANOTECHNOLOGY IN BREAST CANCER

G. Bianchini, A. Bottini

GEPARSEPTO

A randomized phase III trial comparing neoadjuvant chemotherapy with weekly nanoparticle-based paclitaxel with solvent - based paclitaxel followed by anthracycline/cyclophosphamide for patients with early breast cancer

M. Untch

Pearls from the European Cancer Conference 2015

C. Tondini

10:30

ONGOING RESEARCH: EARLY DISEASE

A. Fabi, M. Mansutti

ADAPT

Adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: study

protocol for a prospective, multi-center, controlled, non-blinded, randomized, investigator initiated phase II/III trial

G. Arpino

ETNA

Neoadjuvant chemotherapy with nab-paclitaxel in women with HER2-negative high-risk breast cancer nab-paclitaxel 150 mg/m² day 1, 8, 15 for 4 cycles 28 days followed by AC or FEC for 4 cycles vs Weekly paclitaxel for 4 cycles followed by AC or FEC for 4 cycles both followed by surgery

M. Zambetti

PER-ELISA

PERtuzumab-trastuzumab plus Ietrozo-Le In endocrine Sensitive breast cancer: a phase II neoAdjuvant study

M.V. Dieci

11:15

Coffee break

11:30

ONGOING RESEARCH: ADVANCED DISEASE

MT. Ionta, E. Simoncini

GOIM

A multicenter phase II trial of nab-paclitaxel and capecitabine as first line treatment in HER2-negative metastatic breast cancer

S. Cinieri

EFFECT

Evaluation of the efficacy and impact on patient functioning of two doses of nab-paclitaxel in elderly (>65 yrs) breast cancer patients

L. Biganzoli

TNACITY

Phase 2/3, multi-center, open-label, randomized study of weekly Nab-paclitaxel in combination with gemcitabine or carboplatin, vs gemcitabine / carboplatin, as first-line treatment in TNMBC Abraxane 125mg/ m², Gemcitabine 1000mg/ m², Carboplatin AUC2 days 1,8 cycles 21 days

S. Spazzapan

ABRAMYO

Phase I-II, multicenter open label study in patients with previously untreated metastatic breast cancer Nab-paclitaxel 100_125 mg/ m² and with LDox 20_25 mg/ m² will be administered on days 1, 8, 15 of a 28-day cycle until disease progression

P. Papaldo

SNAP

A randomized phase II study evaluating three different schedules of nab-paclitaxel as maintenance therapy

A. Gennari

GIM 13 - AMBRA

Longitudinal, observational study on the choices of chemotherapy for HER2-negative metastatic breast cancer in the clinical practice

M. Cazzaniga

REAL WORD STUDY

Activity and safety of albumin-bounded paclitaxel (nab-paclitaxel) in second and further chemotherapy lines for metastatic breast cancer (MBC): a real world clinical practice multicenter italian experience

M. Cazzaniga

TACT

A phase II randomized, open-label study evaluating the addition of trastuzumab to (nabTM)-paclitaxel as first line treatment in primary HER2 negative metastatic breast cancer patients with HER2 positive Circulating Tumor Cells (CTCs)

D. Generali

ROUNDTABLE

A. Bottini, F. Cognetti, P. Conte, M. De Laurentiis, S. De Placido, L. Dogliotti, L. Gianni, G. Mustacchi, P. Pronzato, F. Puglisi

13:30

Conclusions

